Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Multiple Myeloma 23Lymphoma, Large B-Cell, Diffuse 17Recurrence 7Neoplasms, Plasma Cell 5Lymphoma, T-Cell, Peripheral 4Lymphoma, Mantle-Cell 4Leukemia, Myeloid, Acute 4Neoplasms 3Myelodysplastic Syndromes 3Lymphoma, B-Cell 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Paraproteinemias 2Neoplasms by Histologic Type 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, Non-Hodgkin 2Lymphoma, Follicular 2Lymphoma, Extranodal NK-T-Cell 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hodgkin Disease 2Hematologic Diseases 2Colorectal Neoplasms 2Blood Protein Disorders 2Sezary Syndrome 1Renal Insufficiency 1Neuroblastoma 1Mycosis Fungoides 1Lymphoma, Large-Cell, Anaplastic 1

Interventions

spartalizumab 2pegaspargase 2Methylprednisolone 2Etoposide 2Dexamethasone 2toripalimab 1ruxolitinib 1Valproic Acid 1Valganciclovir 1Rituximab 1Liquid Biopsy 1Lenalidomide 1Gemcitabine 1Doxorubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Epstein-Barr Virus Infections × Lenalidomide × Clear all
NCT04084626 2022-01-05

PD1 Antibody and Lenalidomide as a Treatment for EBV-HLH or CAEBV

Beijing Friendship Hospital

Phase 3 Unknown
40 enrolled

Epstein-Barr Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡